Mediderm® products are a complete therapy specially formulated for severe dry skin conditions such as psoriasis, eczema and atopic dermatitis.

Dermatoses and accompanying severe dry skin conditions are very common in developed countries and rising in numbers. Atopic dermatitis (AD) is one of the most common disorders affecting up to 20% of the population, depending on the country.

Another inflammatory skin disease is psoriasis, which affects around up to 5% of the population. There is 70% risk of psoriasis if both parents are affected.

In all dermatoses with the inflamed states, the dryness and increased mitotic activity of epidermal cells are observed. The symptoms of dry skin apart from roughness may include: peeling and cracking of the epidermis, lichenification or erythema.

Topical skin treatments intended for patients affected by problems of severe skin dryness, should have a wide spectrum of activity; appropriate hydration and replenishing of the skin epidermis, which will allow reducing the number and amount of used drugs, including local glucocorticosteroids (so-called steroid-sparing effects).

Prevalence of psoriasis by sex (year of data survey given, not of publication).

According to the WHO’s Global report on psoriasis, 2016.

Since psoriasis and AD usually affects large area of the skin, the patient requires large amounts of rich moisturisers to replenish the natural skin lipid coat of the skin.

Recommended weekly amount of moisturising and replenishing preparations for atopic skin is 150-250 g for children and 250-500 g for adults. The maximum duration time of active hydration is 6 h, therefore they should be used at least 3 times a day.

A key element in the management of psoriasis, eczema and AD is regular moisturising and replenishing of the skin epidermis which will ensure proper hydration of deeper layers of the epidermis and regeneration of the skin lipid coat.

Mediderm® CREAM meets the requirements of patients suffering from inflammatory dermatoses. Three different pack sizes: 100 g, 500 g and the largest 1 kg allow choice according to the patient’s needs (travel size vs. home use).

The amount of 1 kg of cream is sufficient for about 2 weeks’ treatment.

Mediderm® products and compliance

It can be very difficult for patients suffering from psoriasis to find the right topical treatment product for daily use. In order to maintain compliance (observing therapy recommendation), the topical treatments, apart from effectiveness, should also be characterised by the convenience of use and efficiency.

Non-compliance with medical recommendations was observed in nearly 25% of patients using moisturising and replenishing preparations. The decisive factors were: unpleasant smell, oily consistency, staining of clothing and price.

Mediderm® products do not contain SLS, parabens, fragrances and colour, and due to their light formula are well absorbed and do not stain clothes or bedding.

The most common causes of allergies in topical products are fragrances and preservatives. The addition of moisture-locking substances (e.g. urea) can also be irritating.

Regular use of Mediderm® products reduces irritation and allergies.

Mediderm® in a complementary therapy

Glucocorticosteroids are still one of the standard therapies in the treatment of inflammatory dermatoses such as psoriasis or atopic dermatitis. Many patients (some studies say as high as 75%) may experience corticosteroid phobia. So alternative therapies have to be available.

A good example avoiding glucocorticosteroids is the use of complementary therapy with appropriate moisturising and replenishing preparations.

Thanks to such a procedure, the following results have been achieved:

  • shortening of the time of exacerbations, reducing the number of symptom recurrences and preserving the improvement after corticotherapy in psoriasis;
  • reduction of treatment time in AD;
  • significant improvement of scaly layer hydration in psoriasis;
  • significant reduction in corticosteroid consumption in children with AD;
  • reduction of the risk of tachyphylaxis with corticosteroids.

Mediderm® products fulfil such expectations of complementary therapy, they have a positive effect on the condition and appearance of the skin. It is important not to be limited to the periods of severe inflammation but also the use continued in period of remission and then for prevention.

Mediderm® preparations have been dermatologically tested in patients with psoriasis and AD.


30-721 KRAKÓW

Do you want to partner with us?


    The Administrator of your personal data is Farmina sp. z o.o., ul. Lipska 44, 30-721 Kraków, Poland, e-mail:
    Your personal data will only be used to process your inquiry and will not be sent to third parties. You have the right to access your personal data; to request correction (revision) of your personal data; to request the deletion of personal data. You voluntarily agree to the processing of your data.